Published in Clin Pharmacokinet on March 01, 1990
Detection of potential drug interactions - a model for a national pharmacy register. Eur J Clin Pharmacol (2006) 0.91
Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids. Br J Clin Pharmacol (2002) 0.83
Safety of acid-suppressing drugs. Dig Dis Sci (1995) 0.83
Role of eicosanoids, nitric oxide, and afferent neurons in antacid induced protection in the rat stomach. Gut (1993) 0.78
Effect of an antacid containing magnesium and aluminum on absorption, metabolism, and mechanism of renal elimination of pefloxacin in humans. Antimicrob Agents Chemother (1994) 0.77
The effects of magnesium hydroxide on the absorption and efficacy of two glibenclamide preparations. Br J Clin Pharmacol (1991) 0.77
A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKD. Semin Dial (2015) 0.77
ABT-773: pharmacokinetics and interactions with ranitidine and sucralfate. Antimicrob Agents Chemother (2003) 0.77
Lack of pharmacokinetic interaction between linezolid and antacid in healthy volunteers. Antimicrob Agents Chemother (2006) 0.77
Determination and characterization of metronidazole-kaolin interaction. Saudi Pharm J (2014) 0.75
In-vitro interaction of a novel immunosuppressant, FK 506, and antacids. J Pharm Pharmacol (1991) 0.75
MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene (2007) 10.79
Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene (2011) 1.75
Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors. Oncogene (2007) 1.62
MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways. Oncogene (2011) 1.57
Is radical scavenging necessary in the treatment of inflammatory bowel disease? Gastroenterology (1991) 1.39
Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med (1995) 1.30
Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model. Br J Cancer (2007) 1.23
QuickMap: a public tool for large-scale gene therapy vector insertion site mapping and analysis. Gene Ther (2009) 1.11
Downregulation of E-cadherin is an essential event in activating beta-catenin/Tcf-dependent transcription and expression of its target genes in Pdcd4 knockdown cells. Oncogene (2009) 1.03
Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol (1995) 0.97
Identification of a novel nuclear factor-kappaB sequence involved in expression of urokinase-type plasminogen activator receptor. Eur J Biochem (2000) 0.96
Drug-induced fibrosing colonopathy in inflammatory bowel disease after 5-ASA? Dig Dis Sci (1999) 0.95
Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer. Ann Surg (1997) 0.91
Influence of autologous blood transfusion on natural killer and lymphokine-activated killer cell activities in cancer surgery. Vox Sang (1997) 0.90
Effect of olsalazine and mesalazine on human ileal and colonic (Na+ + K+)-ATPase. A possible diarrhogenic factor? Clin Investig (1993) 0.89
A region between -141 and -61 bp containing a proximal AP-1 is essential for constitutive expression of urokinase-type plasminogen activator receptor. Eur J Biochem (1999) 0.89
Prognostic influence of blood transfusion on minimal residual disease in resected gastric cancer patients. Anticancer Res (1997) 0.89
Modulation of immune response by blood transfusion: evidence for a differential effect of allogeneic and autologous blood in colorectal cancer surgery. Shock (1997) 0.83
Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules. Br J Cancer (2010) 0.83
Perisurgical erythropoietin application in anemic patients with colorectal cancer: A double-blind randomized study. Surgery (1996) 0.82
Analysis of self-inactivating lentiviral vector integration sites and flanking gene expression in human peripheral blood progenitor cells after alkylator chemotherapy. Hum Gene Ther (2010) 0.80
Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires JNK1-dependent and -independent signaling modules. Oncogene (1998) 0.80
Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine. Eur J Clin Pharmacol (1984) 0.80
Identification of an histone H3 acetylated/K4-methylated-bound intragenic enhancer regulatory for urokinase receptor expression. Oncogene (2006) 0.79
The prognostic impact of the urokinase-type plasminogen activator system is associated with tumour differentiation in gastric cancer. Eur J Surg Oncol (1996) 0.79
Effect of short-term topical corticosteroid treatment on mucosal enzyme systems in patients with distal inflammatory bowel disease. Hepatogastroenterology (1999) 0.79
Ras regulation of urokinase-type plasminogen activator. Methods Enzymol (2001) 0.79
Multiple displacement amplification enables large-scale clonal analysis following retroviral gene therapy. J Virol (2007) 0.79
[Mebendazole therapy in echinococcosis. Long-term study and course parameters in 8 patients]. Dtsch Med Wochenschr (1984) 0.78
Increased dose-response relationship of liver plasma membrane adenylate cyclase to glucagon stimulation in diabetic rats. A possible role of the guanyl nucleotide-binding regulatory protein. Diabetologia (1982) 0.78
F2A sequence linking MGMT(P140K) and MDR1 in a bicistronic lentiviral vector enables efficient chemoprotection of haematopoietic stem cells. Cancer Gene Ther (2012) 0.78
[Insulin, glucagon binding and adenylate cyclase activity of liver plasma membranes in streptozotocin-diabetic rats]. Verh Dtsch Ges Inn Med (1978) 0.77
Less advanced stages of colon cancer in patients with type 2 diabetes mellitus: an unexpected finding? Exp Clin Endocrinol Diabetes (2012) 0.76
A real time PCR based approach for the quantitative detection of FUS-CHOP fusion transcripts in human liposarcoma. Adv Med Sci (2012) 0.75
Different iron-chelating properties of aminosalicylates. Gastroenterology (1992) 0.75
[2 patients with melena and hematochezia of undetermined origin]. Internist (Berl) (1985) 0.75
[A patient with cavernous lung foci, arthralgias and eye symptoms]. Internist (Berl) (1983) 0.75
Studies on the in vitro binding of D-penicillamine to cholestyramine. Experientia (1982) 0.75
Inhibition of human colonic (Na+ + K+)-ATPase by arachidonic and linoleic acid. Naunyn Schmiedebergs Arch Pharmacol (1986) 0.75
Absence of in vivo and in vitro interactions of an aluminum hydroxide, magnesium hydroxide containing antacid with cimetidine in patients with peptic ulcer. Z Gastroenterol (1983) 0.75
COX-2, TFF1, and Src define better prognosis in young patients with gastric cancer. J Surg Oncol (2013) 0.75
Can cyclosporin prevent proctocolectomy in severe steroid-refractory ulcerative colitis? Lessons from a case report. Dig Dis Sci (1993) 0.75
Olsalazine-related diarrhoea: does rat intestine adapt in vivo? Scand J Gastroenterol (1992) 0.75
Pneumoperitoneum following colonoscopy in a patient with a solitary rectal ulcer. Endoscopy (1991) 0.75
Determination of the pK values of 5-aminosalicylic acid and N-acetylaminosalicylic acid and comparison of the pH dependent lipid-water partition coefficients of sulphasalazine and its metabolites. Arzneimittelforschung (1985) 0.75
[Acute epigastric disorders and recurring thrombophlebitis]. Internist (Berl) (1983) 0.75
[The glucagon-dependent stimulation of cyclic AMP--a new diagnostic liver test?]. Z Gastroenterol (1983) 0.75
[Salazosulfapyridine: old and new therapy concepts in inflammatory bowel diseases]. Dtsch Med Wochenschr (1985) 0.75
Studies on the in vitro interactions of cimetidine with commercial antacid preparations and chemically pure components. Arzneimittelforschung (1984) 0.75
Salicylate and diarrhea. Gastroenterology (1987) 0.75
Studies on the in vitro interaction of D-penicillamine with antacids. Arzneimittelforschung (1983) 0.75
Comparative pharmacokinetics of sulphasalazine and sulphapyridine after rectal and oral administration to patients with ulcerative colitis. Eur J Clin Pharmacol (1984) 0.75
Lack of effect of haemodialysis on mebendazole kinetics: studies in a patient with echinococcosis and renal failure. Eur J Clin Pharmacol (1984) 0.75